Objective-Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by the infiltration of multiple tissues with lipid-laden histiocytes. Cardiovascular involvement is frequent in ECD and leads to a severe prognosis. The objective of this study was to determine whether an alteration of lipid metabolism participates in the lipid accumulation in histiocytes and the cardiovascular involvement in ECD. Approach and Results-An analysis of plasma lipid levels indicated that male ECD patients carrying the BRAF V600E (B-Raf proto-oncogene, serine/threonine kinase) mutation exhibited hypoalphalipoproteinemia, as demonstrated by low plasma HDL-C (high-density lipoprotein cholesterol) levels. Capacity of sera from male BRAF V600E ECD patients to mediate free cholesterol efflux from human macrophages was reduced compared with control individuals. Cardiovascular involvement was detected in 84% of the ECD patients, and we reported that the presence of the BRAF V600E mutation and hypoalphalipoproteinemia is an independent determinant of aortic infiltration in ECD. Phenotyping of blood CD14 + cells, the precursors of histiocytes, enabled the identification of a specific inflammatory signature associated with aortic infiltration which was partially affected by the HDL phenotype. Finally, the treatment with vemurafenib, an inhibitor of the BRAF V600E mutation, restored the defective sera cholesterol efflux capacity and reduced the aortic infiltration. Conclusions-Our findings indicate that hypoalphalipoproteinemia in male ECD patients carrying the BRAF V600E mutation favors the formation of lipid-laden histiocytes. In addition, we identified the BRAF status and the HDL phenotype as independent determinants of the aortic involvement in ECD with a potential role of HDL in modulating the infiltration of blood CD14 + cells into the aorta. Visual Overview-An online visual overview is available for this article.
rdheim-Chester disease (ECD) is a rare non-Langerhans cells histiocytosis characterized by the infiltration of tissues by foamy CD68
+ CD1a − histiocytes. 1 This multisystemic disease primarily involves the bones, retroperitoneum, heart and aorta, and less frequently the lungs, skin, retroorbital tissues, central nervous system, and pituitary gland. Cardiovascular involvement (>50% of patients) is frequently underdiagnosed and is associated with a severe prognostic of ECD. 2 Histiocytes in ECD are thought to originate from myeloid CD34 + and CD14 + progenitor cells. 3, 4 However, the mechanisms underlying histiocytes infiltration and formation are largely unknown. Almost 60% of ECD patients harbor the BRAF V600E (B-Raf proto-oncogene, serine/threonine kinase) mutation. 5 This discovery provided important therapeutic options in recent years. Nevertheless, these findings' implications in ECD physiopathology and, in particular, in the accumulation of foamy histiocytes have not been elucidated. 5 Infiltrated foamy histiocytes in ECD tissues were originally described as lipid-laden macrophage-like cells. 6 Lipid accumulation in the form of lipid vacuoles is indeed observed in histiocytes in certain cases 7, 8 but does not constitute a constant feature in ECD. 9, 10 Cellular lipid accumulation usually reflects an impaired lipid homeostasis, which may be consecutive to an alteration of lipid metabolism. Inflammatory diseases are frequently associated with dyslipidemia as classically observed in rheumatoid arthritis, systemic lupus erythematosus, Crohn disease, or sepsis. 11 Among the plasma lipid abnormalities observed in these diseases, a common feature is the low plasma HDL (high-density lipoprotein) phenotype characterized by both reduced levels and biological activity, that is, the cholesterol efflux capacity (CEC) of HDL, which is a marker of disease activity. 12, 13 Although it is now well accepted that ECD is an inflammatory disease, 14, 15 only a small number of case report studies examined lipid metabolism in ECD patients, which resulted in contrasting observations. [16] [17] [18] Indeed, no study attempted an extensive investigation of lipid metabolism in a large cohort of ECD patients was conducted to date. The goal of the present study was to determine whether inflammation occurring in ECD is associated with an alteration of lipid metabolism, which might favor lipid-laden histiocyte formation and disease severity. Extensive investigation of the lipid metabolism in a large monocentric cohort of 78 ECD patients led us to demonstrate that male BRAF V600E mutation carriers exhibited a low HDL phenotype, which contributes to impaired macrophage lipid homeostasis and then might participate in the formation of foamy histiocytes in ECD. Moreover, the presence of the BRAF V600E mutation was strongly associated with cardiovascular involvement in ECD, with the low HDL phenotype being identified in this study as an independent determinant of aortic infiltration (AI).
Materials and Methods
Data available on request from the authors.
Patients
Fasting blood samples were obtained from 78 patients with ECD (60 males and 18 females, mean age: 61±10 years [range, 18-84 years]) followed in the Department of Internal Medicine, Pitié-Salpêtrière Hospital, Paris, France, between December 2012 and July 2015. For all patients, ECD was diagnosed based following the consensus guidelines for the diagnosis and clinical management of ECD. 19 The detection of the BRAF V600E mutation was performed by multiplex picodroplet digital polymerase chain reaction (Raindance Technologies) as previously described. 5 The prevalence of the BRAF V600E mutation was 64% (50 patients over 78) in ECD patients. At the time of the collection, the patients were either free of any treatment (n=42) or received treatment (pegylated interferon-α [pegIFNα; n=31], infliximab [n=10], vemurafenib [n=14], or others [n=6]). In certain cases, fasting blood samples were collected before and after the therapies with either infliximab (n=3), pegIFNα (n=6), vemurafenib (n=6), or others (n=9). Many patients were taking lipid-lowering drugs (n=24), including HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors (n=20), fibrates (n=2), a combination of both (n=1) or ezetimibe (n=1). Heart involvement, such as cardiac and aortic infiltration of histiocytes (cardiac infiltration [CI] and AI, respectively), was detected by both heart magnetic resonance imaging and gated computed tomographic scans in 75 patients as described in our previous study. 2 More precisely, cardiac computed tomography and image analysis were performed with a dual-source 128-slice scanner (Somatom Definition Flash, Siemens Medical Solutions, Germany). A minimum of 65 mL contrast agent (Iomeron 400 mgI/mL) was administered intravenously at a flow rate of 6 mL/s followed by 50 mL saline flush at 6 mL/s. A group of 21 normolipidemic healthy control individuals (13 males and 8 females, mean age: 52±11 years [range, 26-75 years]) was included as a reference group for the quantification of plasma lipid levels and the evaluation of serum CEC. This study was approved by the ethics committee Ile de France III (No. 2011-A00447-34) and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all of the patients.
Sample Preparation
Venous blood samples were collected by venipuncture from the antecubital vein into sterile BD Vacutainer tubes containing clot activator and EDTA-containing tubes (final concentration of EDTA, 1 mg/mL), and serum and plasma were separated immediately by low-speed centrifugation at 2500 rpm for 20 minutes at 4°C and were stored at −80°C until use.
Biochemical Analysis
The lipid (triglycerides, total cholesterol, HDL-C (HDL cholesterol), Lp(a) [lipoprotein(a)], glucose, CRP [C-reactive protein], and Apo AI, ApoB, and apoE [apolipoproteins]) contents in the plasma were quantified with an Autoanalyzer (Konelab 20). Reagent kits were used to determine total cholesterol, triglyceride, glucose, CRP ultra-sensitive, apoE, direct HDL-C (Thermo Fisher Scientific), and Lp(a) (Diasys) levels. Fasting plasma LDL-C (low-density lipoprotein cholesterol) was calculated using the Friedewald formula. Plasma ApoA-I and ApoB were determined using immunoturbidimetric assays (Thermo Fisher Scientific reagents and calibrators; Diasys reagents and calibrators).
Macrophage Cholesterol Efflux
The human THP-1 monocytic cell line was obtained from the American Type Culture Collection and was maintained in culture in 5% CO 2 at 37°C in RPMI (Roswell Park Memorial Institute) medium containing 10% heat-inactivated fetal bovine serum, 2 mmol/L L-glutamine, and 80 U/mL penicillin/80 μg/mL streptomycin. The human ABCA (ATP-binding cassette A) 1 knockout (KO) THP-1 cells were kindly provided by Pr. W. Jessup (ANZAC Research Institute, Sydney, Australia) and previously described in details. 20 In brief, the stable silencing of ABCA1 in THP-1 cells was achieved by transfection with a SureSilencing shRNA plasmid (Clone ID 1, Cat. KH02595P, SABiosciences). Monoclonal ABCA1 KO THP-1 cell lines were selected with puromycin (250 ng/mL), and knockdown of ABCA1 was confirmed by Western Blot. THP-1 monocytes were grown in the presence of 50 ng/mL phorbol 12-myristate 13-acetate for 3 days to induce differentiation into macrophages. ApoB-depleted or the whole serum CEC from human THP-1 macrophages was evaluated as previously described. 21 Human THP-1 macrophages were labeled with 1 μCi/mL [3H]cholesterol for 24 hours in the presence of 10% of serum from the control or patients diluted in RPMI media. Human macrophages were later equilibrated in RGGB (RPMI 1640 supplemented with 50 mmol/L glucose, 2 mmol/L glutamine, and 0.2% bovine serum albumin) medium for an additional period of 16 hours. Cellular cholesterol efflux to 2.5% ApoB-depleted or whole serum was assayed in RGGB medium for a 4-hour chase 
Blood Monocyte Isolation and Gene Expression Analysis
Circulating CD14-positive monocytes were isolated from fresh blood samples by automated magnetic separation using King Fisher (Thermo) with magnetic beads coated with an anti-CD14 monoclonal antibody (Dynabeads CD14, Invitrogen). Total RNA was extracted using the TRIzol reagent and was purified using a NucleoSpin RNA II kit (Macherey-Nagel) according to the manufacturer's instructions. Reverse transcription of the RNA and real-time quantitative polymerase chain reaction were performed as previously described. 22 The amount of mRNA for the genes of interest was normalized to those of 5 different housekeeping genes (human δ-aminolevulinate synthase, human α-tubulin, human heat shock protein 90 kDa alpha, human 18S rRNA, and human non-POU domain containing, octamer binding). The data are expressed as a fold change in the mRNA expression relative to the values of the untreated ECD patients, which do not carry the BRAF V600E mutation (wild type). A list of primers used is available in Table I in the online-only Data Supplement.
Statistical Analyses
The data are shown as the mean±SEM. The experiments were performed in triplicate. Comparisons of 2 groups were performed by a 2-tailed Student t test. Comparisons of ≥3 groups were performed by an ANOVA with a Dunnett post-test. Sex-and ABCA1-specific effects were analyzed by a 2-way ANOVA with a Tukey post-test. Statistical analyses were performed using the Prism software from GraphPad (San Diego, CA). Logistic regression analyses were used to determine the association between CI or AI and the numeric or categorical variables. The adjusted odds ratios correspond to the impact of 1 SD increase in the independent variable on the variability of the dependent variable. For skewed variables, the raw data were logarithmically transformed before the analyses. Logistic regression analyses were performed using the R statistical software computer program version 3.3.2 (R Foundation for Statistical Computing).
Results

Presence of the BRAF
V600E Mutation Is Associated With a Low HDL Phenotype in ECD
Elevated circulating C-reactive protein (CRP) levels were observed in the untreated patients, confirming the inflammatory status of ECD ( Table 1 ). The analysis of the fasting plasma lipid levels in the untreated ECD patients not receiving any lipid-lowering therapy indicated that the plasma triglycerides and Lp(a) concentrations were more elevated in ECD than in the control individuals (+35% and +92%, respectively, P<0.05), and this latter effect was only observed in the patients carrying the BRAF V600E mutation. By contrast, the ECD patients exhibited lower plasma total cholesterol and HDL-C levels than the control individuals (−13%, P<0.05 and −36%, P<0.0005, respectively), with the values for the plasma HDL-C levels highlighting that the ECD patients, mostly BRAF V600E carriers, displayed hypoalphalipoproteinemia (<40 mg/dL). In a consistent manner, circulating levels of ApoA-I, the major apolipoprotein forming HDL, were lower in the ECD patients than in the control individuals (−17%, P<0.05), an effect attributable to those carrying the BRAF V600E mutation. Plasma LDL-C, ApoB, and ApoE levels in the untreated ECD patients were in the normal range and were not different to those in the control subjects. Plasma HDL levels were inversely correlated to those of CRP in untreated ECD patients not receiving any lipid-lowering therapy (r=−0.48, P=0.0025), a result that is in agreement with the strong anti-inflammatory properties of HDL particles. However, this effect seems to be influenced by the BRAF status ( Figure I in the online-only Data Supplement).
A similar plasma lipid and apolipoprotein phenotype was observed when the ECD patients receiving lipid-lowering therapy were included in the analysis (Table II in the online-only Data Supplement). Interestingly, plasma HDL-C and ApoA-I levels in ECD patients treated with vemurafenib were no longer statistically different to those from control individuals, whereas pegIFNα and infliximab therapies were without any apparent effect. Thus, vemurafenib was able to correct hypoalphalipoproteinemia in BRAF V600E carriers (HDL-C=43.6±6.6 mg/dL in the vemurafenib group). Analysis of the effect of vemurafenib in a subset of ECD patients carrying the BRAF V600E mutation (n=6) confirmed the capacity of this treatment to increase plasma HDL-C levels ( Figure 1A ). Moreover, a significant increase in the plasma triglycerides levels was equally detected following vemurafenib treatment (+36%, P<0.05 versus untreated ECD patients). It is also to note that circulating triglycerides concentrations in patients treated with pegIFNα were significantly more elevated than in control individuals (+76%, P<0.0005). Finally, the treatment with pegIFNα led to an elevation of plasma ApoE levels in ECD patients (+23%, P<0.05 versus untreated ECD patients).
Sex-Dependent Hypoalphalipoproteinemia in ECD
A more detailed analysis revealed that hypoalphalipoproteinemia in ECD was mostly harbored by male BRAF V600E ECD patients, although normal plasma HDL-C levels were detected in male wild-type and female ECD individuals whatever the BRAF status ( Figure 1B ). Although treatment with vemurafenib abolished the significance of the sex effect on circulating HDL-C levels, this latter did not, however, abolish hypoalphalipoproteinemia in male patients carrying the BRAF V600E mutation when all patients were included in the analysis (V600E: 29.21±1.86 mg/dL versus V600E+Vemurafenib: 36.37±4.94 mg/dL, Figure 1B ).
Taken together, these data indicate that ECD is characterized by hypoalphalipoproteinemia which is primarily harbored by male individuals carrying the BRAF V600E mutation.
Reduced Macrophage ABCA1-Mediated Serum CEC in ECD
High-density lipoproteins represent the major cholesterol acceptors from cells and play a pivotal role in the return of cellular cholesterol back to the liver for elimination through a mechanism named reverse cholesterol transport. In this context, a reduction of plasma HDL particles levels as that observed in ECD could be associated with an impaired cellular cholesterol export and could contribute to cell cholesterol accumulation and lipid-laden histiocyte formation in ECD. To address this hypothesis, we tested the capacity of the ECD serum, which contains the whole HDL particles to mediate export of cholesterol, that is, cholesterol efflux, from human macrophages as ECD histiocytes are thought to originate from the monocyte-macrophage lineage. As shown in Figure 2A , the capacity of the ECD serum to promote cholesterol efflux from human THP-1 macrophages was markedly reduced (−16%, P<0.05) compared with that of the serum from healthy normolipidemic control subjects (Control); this effect being independent of the patients' age ( Figure II in the online-only Data Supplement). Coherent with the respective plasma HDL-C levels, this effect mostly resulted from the specific reduction of macrophage CEC of the serum from the male BRAF V600E ECD patients (−22%, P<0.05 versus male control serum), whereas that from either the wild-type or female patients was not altered (Figure 2A) . Interestingly, the sera CEC from the BRAF V600 ECD patients treated with vemurafenib was not significantly different from the sera CEC from the control individuals suggesting that the inhibition of BRAF V600E might restore the altered CEC in the mutated male patients. Coherent with this observation, vemurafenib allowed for an increased CEC in a subset of the ECD patients carrying the BRAF V600E mutation (5 over a total of 6 patients, P=0.05) ( Figure 2B ). Although the pegIFNα therapy was able to elevate the ApoE level in ECD patients (Table II in the online-only Data Supplement), no concomitant increase of macrophage CEC was observed in the presence of sera from ECD patients treated with pegIFNα, and that, whatever the BRAF status (data not shown).
Because ApoB-containing lipoproteins may also contribute to serum CEC, 23 the experiments were replicated with ApoB-depleted serum ( Figure 2C ). The results obtained with the ApoB-depleted serum were similar to those obtained with total serum, confirming that reduced CEC in patients carrying the BRAF V600E mutation was very likely because of the low plasma HDL levels observed in this subgroup of patients. Cholesterol efflux to HDL from human macrophages is proposed to be mainly mediated by the ABCA1 transporter. 20, 22 Thus, to determine if the ABCA1-mediated cholesterol efflux pathway is involved in this effect, we tested the CEC from the ECD patients in ABCA1 KO human THP-1 macrophages. 20 Regardless of the BRAF status, the capacity of the ECD serum to mediate cholesterol efflux was similar to that of the control serum in ABCA1 KO cells ( Figure 2D ), indicating that ECD serum exhibited an impaired ABCA1-mediated CEC. As a whole, our results suggest that the hypoalphalipoproteinemia observed in the male BRAF V600E ECD patients is accompanied by an impaired macrophage ABCA1-mediated cholesterol efflux that might contribute to lipid-laden histiocyte formation in ECD.
BRAF
V600E Status and HDL Phenotype Are Strong Independent Determinants of AI in ECD
The serum CEC from macrophages is strongly associated with the incidence of coronary heart diseases. 24 A low HDL phenotype is frequently observed in inflammatory diseases associated with an increased cardiovascular risk, and the evaluation of CEC as a metric of HDL function is a strong marker of disease activity in systemic lupus erythematosus and rheumatoid arthritis. 12, 13 The cardiovascular system is affected in up to 75% of ECD patients with pericardial and myocardial infiltration as well as perivascular infiltration of the aorta (coated aorta). 2 An assessment of the cardiovascular involvement in ECD patients (n=74) by both magnetic resonance imaging and computed tomography, in the present study, revealed the presence of a CI or an AI in 61% and 77.4% of the cases ( Figures 3A and 3B ), respectively, with 49.3% exhibiting both CI and AI ( Figure 3C ). Then, cardiovascular infiltration was observed in 84.1% of the patients confirming the high frequency of cardiovascular involvement in ECD. Interestingly, infiltration was mostly detected in the patients carrying the BRAF V600E mutation, indicating that the presence of the mutation was associated with histiocyte infiltration in the heart and aorta. Moreover, it is relevant to note that the male patients appeared more affected than the female patients ( Figure III in the online-only Data Supplement).
In agreement with this observation, the presence of the BRAF V600E mutation was associated with an increased risk of CI and AI (odds ratio per 1 SD increase in BRAF V600E status, 4.92; 95% confidence interval, 1.46-18.56; P=0.0155; (Table 2 and 6.27; 95% confidence interval, 1.69-24.8; P=0.0066; Table 3 , respectively). In addition, several others biological and clinical variables were associated with heart infiltration by a univariate logistic regression. Body mass index or age and hypertension and CRP were each linked to an increased risk of either CI or AI in ECD (Tables 2 and 3) , whereas plasma HDL-C levels were inversely associated with the risk of both CI and AI (odds ratio per 1 SD increase in plasma HDL-C levels, 0.51; 95% confidence interval, 0.27-0.87; P=0.0201; Table 2 and 0.33; 95% confidence interval, 0.15-0.61; P=0.0014; Table 3 ). Interestingly, an inverse association between CEC, the metric of HDL function, and AI, but not CI, was equally observed. The combination of those risk factors in a multivariate logistic regression analysis indicated that the BRAF V600E status was a highly significant predictor of cardiovascular infiltration, whereas the protective effect of plasma HDL-C levels remained significant only in AI. A model including the remaining predictors of AI is shown in Figure 3D and highlights that the BRAF V600E status, age, and plasma HDL-C levels were independent risk factors for AI. Those findings indicate that the BRAF V600E status and the low HDL phenotype in ECD contribute to histiocyte infiltration in the aorta. In agreement with the critical role of the BRAF V600E mutation in AI, we observed a marked reduction of AI in ECD patients carrying the BRAF V600E mutation following vemurafenib treatment, although they still exhibited a coated-aorta appearance ( Figure IV in the online-only Data Supplement).
AI Was Associated With a Specific CD14 + Precursor Cell Signature, Which Is Affected by the HDL Phenotype
Histiocytes are proposed to originate from CD14 + precursor cells, 3, 4 and HDL possesses potent anti-inflammatory properties, especially in hampering blood CD14 + monocyte inflammation. 25 To provide a better understanding of the mechanisms involved in heart infiltration in ECD and to precisely define the role of the HDL phenotype in the latter, circulating CD14 + cells from ECD patients were isolated, and the expression of key genes involved in blood cell recruitment and inflammation was analyzed.
The presence of AI in the ECD patients was associated with increased blood CD14 + cell mRNA levels of C-C motif chemokine receptor type 7 (CCR7), C-X3-C motif receptor 1 (CX3CR1), and interleukin-1 receptor antagonist (IL1RA) together with a decrease in C-X-C motif ligand 1 (CXCL1; Table 4 ), whereas the expression of these genes was not altered in the CD14 + cells from patients exhibiting CI. On the other hand, an elevation of integrin subunit alpha 4 (ITGA4) and selectin P ligand (SELPLG) mRNA levels was observed in case of CI in ECD patients. These findings suggest that blood CD14 + cells, possessing a distinct gene expression signature, contribute to CI and AI in ECD.
An in-depth analysis of CCR7, CX3CR1, CXCL1, IL1RA, ITGA4, and SELPLG expression in circulating CD14 + cells according to the BRAF status indicated that the latter were not affected by the presence of the BRAF V600E mutation (data not shown). In contrast, an analysis of the impact of the HDL phenotype on the inflammatory status of blood CD14 + cells in the ECD patients indicated that both CXCL1 and CCR7 mRNA levels were significantly reduced in the ECD patients exhibiting low HDL-C levels (Low; Figure 4 ). On the other hand, the expression of CX3CR1, IL1RA, ITGA4, and SELPLG mRNA levels was not affected by the circulating concentration of HDL. In contrast, our results indicated that a low CEC was accompanied by a significant increase of CX3CR1 mRNA levels in the ECD patients (Figure 4) . Taken together, those findings demonstrate that the inflammatory signature of the circulating CD14
+ cells is associated with cardiovascular infiltration in ECD with the identification of a distinct signature for CI and AI; the AI signature but not that of CI is affected by the HDL phenotype.
Discussion
We here report that the presence of the BRAF V600 mutation and hypoalphalipoproteinemia is positively associated with the high prevalence of AI in ECD. This study notes the critical importance of the BRAF status in determination of plasma HDL levels and in heart infiltration. Moreover, we identified for the first time a link between HDL and infiltration of blood monocytes in aorta, thus providing new clues in the understanding of mechanisms by which HDL protect from cardiovascular disease (CVD).
In ECD, although histiocytes are largely described as lipidladen cells, to date, no study investigated the possible alteration of systemic or cellular lipid metabolism in a large cohort of ECD patients. The exploration of lipid metabolism in a monocentric series of 78 patients indicated that ECD was characterized by hypoalphalipoproteinemia, as testified by low plasma HDL-C (≤40 mg/dL for men and ≤50 mg/dL for women) and ApoA-I levels. Interestingly this low HDL phenotype was only harbored by the male ECD patients carrying the BRAF V600E mutation, suggesting that the RAS/RAF/MEK/ERK pathway might play a role in HDL metabolism. Such a hypothesis is supported by in vitro studies, indicating that the inhibition of this pathway led to an increase in both ApoA-I expression and secretion in hepatic cells. 26, 27 Moreover, in the present study, the treatment with vemurafenib, an inhibitor of BRAF
V600E
, increased HDL-C in a subset of ECD patients and abolished hypoalphalipoproteinemia in the whole cohort of patients. However, further investigations are needed to elucidate the link between the BRAF status and HDL metabolism in ECD. By contrast, the pegIFNα therapy was without effect on plasma HDL-C levels but led to an increase of circulating triglycerides and ApoE concentrations, the mechanisms that underlie these latter effects remaining to be elucidated. In agreement with the central role of HDL in the export of cholesterol from cells through the reverse cholesterol transport pathway, hypoalphalipoproteinemia observed in BRAF V600E ECD impaired cholesterol efflux from macrophages through the ABCA1 pathway as demonstrated by our experiments testing CEC of ECD sera onto THP-1 macrophages. In agreement with the effect of vemurafenib on plasma HDL-C levels, the sera from ECD patients carrying the BRAF V600E mutation and treated with vemurafenib displayed CEC values that were comparable to the control individuals. These results led us to propose that the low HDL phenotype observed in ECD might contribute to the formation of lipid-laden histiocytes frequently reported in the literature. Moreover, the fact that this phenotype was restricted to patients carrying the BRAF V600E mutation, mostly males, might explain why the presence of lipid vacuoles into histiocytes is not systematically observed in all ECD cases. [7] [8] [9] [10] A low HDL phenotype, characterized by low circulating concentrations of HDL, together with an alteration of the biological functions of HDL is a common feature of inflammatory diseases associated with a high risk of CVD as previously reported in systemic lupus erythematosus and rheumatoid arthritis. 12, 13 The association of HDL with CVD was proposed to mainly result from the atheroprotective functions of HDL, notably their capacity to promote macrophage cholesterol efflux, which is largely reported to be inversely associated with atherosclerosis and CVD. 24, [28] [29] [30] Here, we extend our knowledge on the cardioprotective action of HDL by uncovering the importance of HDL in histiocyte infiltration into heart. Indeed, we observed that circulating HDL levels were inversely associated with CI, with an independent protective effect of HDL on AI as shown in the multivariate analysis. Although further analyses are required to elucidate the exact mechanisms underlying this effect thoroughly, the present study allows us to propose that the modulation of the inflammatory phenotype of circulating CD14 + cells by HDL might contribute to the reduced cell infiltration into the aorta of CCR7 (A, G), CX3CR1 (B, H), CXCL1 (C, I), IL1RA (D, J) , ITGA4 (E, K), and SELPLG (F, L) mRNA levels isolated from blood CD14 + cells in ECD patients (n=63) according to either the low HDL phenotype (A-F) or the serum cholesterol efflux capacity (CEC; G-L) from ECD patients. A low HDL phenotype (Low) is considered for plasma HDL-C levels ≤40 mg/dL for men and ≤50 mg/dL for women. The values of the plasma HDL-C (HDL cholesterol) levels >40 mg/dL for men and >50 mg/dL for women are considered High HDL-C (High). Low CEC (Low) and High CEC (High) are defined at the median (Low <0.78 and High >0.78). P values vs patients displaying either a low HDL phenotype (A-F) or a low CEC (G-L).
in ECD. Indeed, we presently demonstrated that the inflammatory phenotype of blood CD14 + cells, which are thought to be the precursors of histiocytes in ECD, 3, 4 was altered in the patients exhibiting heart infiltration. More precisely, a specific set of either chemokine/chemokine receptors (CCR7, CX3CR1, CXCL1, and IL1RA) or integrins (ITGA4 and SELPLG) was differentially expressed in ECD patients with AI or CI, respectively. These findings suggest that the inflammatory phenotype of blood CD14 + cells might contribute, at least in part, to histiocyte infiltration into the cardiovascular system of ECD patients, with a signature that is specific to the infiltrated site. Interestingly, elevated systemic levels of IL-1ra were detected in ECD patients 14 compared with healthy control individuals, and blockade of the IL-1 network was reported, in some cases, to lead to a progression of cardiac involvement. 31 Whereas the chemokine receptor CCR7 was proposed to be involved in the emigration of immune cells, 32 CX3CR1 and CXCL1 as well as adhesion molecules ITGA4 and SELPLG were largely described as promoting the monocyte recruitment into tissues. 33 High-density lipoproteins possess potent antiinflammatory properties, among which is the ability to reduce the inflammatory response of blood CD14 + . 25 Thus, peripheral blood mononuclear cells from subjects displaying low plasma HDL-C levels exhibited a proinflammatory state. 34 In agreement with a possible implication of HDL in AI, the expression of chemokine and chemokine receptors CXCL1 and CX3CR1 was altered in the blood CD14 + cells from the ECD patients according to either circulating levels or functional activities (CEC) of HDL. The observation that the CXCL1 mRNA levels were reduced in patient exhibiting both AI and reduced plasma HDL-C levels may initially seem counterintuitive. However, it has been demonstrated that the leukocyte infiltration in response to chemokines may require their expression at low levels in anatomically restricted areas. Thus, the ability of MCP-1 to elicit monocyte infiltration depends on its being expressed at low levels in specific organs. 35 Therefore, we propose that AI in ECD might require a reduced CXCL1 expression in blood CD14 + cells to respond to local CXCL1. Nevertheless, the observation that CCR7 expression was reduced in blood CD14 + cells from ECD patients exhibiting low HDL-C levels, while this latter was increased in AI, indicates that HDL affects AI independently of blood CD14 + CCR7 expression. In contrast, the expression of integrins (ITGA4 and SELPLG) was not affected by the HDL phenotype of the ECD patients, clearly indicating that distinct mechanisms underlie AI and CI. Thus, a reduction of both the number and functionality of HDL might contribute to AI in ECD through the activation of blood CD14 + cells (CXCL1 and CX3CR1), which might favor their recruitment into the aorta.
This new important information leads us to update the current view about the protective role of HDL in atherosclerosis and, more specifically, the inverse association that exists ) is associated with hypoalphalipoproteinemia which leads to a reduced macrophage cholesterol efflux capacity (CEC) and might contribute to the formation of foamy histiocytes in ECD. We propose a model through which both the HDL (high-density lipoprotein) phenotype and the BRAF status affect aortic infiltration (AI) in ECD. Thus, the independent contribution of HDL-C in aortic infiltration might involve the modulation of CXCL1 expression in blood CD14 + cells. Beyond of the static quantification of HDL-C, CEC, a metric of HDL function, might also contribute in an independent way to AI through modulation of the CX3CR1 expression in blood CD14 + cells. Indeed, AI is associated with a specific inflammatory signature of blood CD14 + cells (↑CX3CR1, ↑CCR7, ↑IL1RA, ↓CXCL1). Then, the BRAF V600E mutation might promote aortic infiltration through effects that are both dependent (HDL-C and CEC) and independent of the HDL phenotype, these latter remaining to be identified. Vemurafenib, an inhibitor of BRAF
, restores macrophage CEC and reduces AI.
between HDL-C, CEC, and CVDs. Indeed, available studies support the concept that the atheroprotective properties of HDL mainly result from its key role in cholesterol efflux from intimal macrophages and reverse cholesterol transport from the arterial wall, which promotes plaque regression. 36 Our findings suggest that in addition to this mechanism, HDL might protect from atherosclerosis development by limiting the recruitment of circulating CD14 + monocytes into the intima of the arterial wall, mainly through the impairment of the CX3CR1 pathway which is crucial in the monocyte recruitment and the atherosclerosis development. 37, 38 In addition to the contribution of the low HDL phenotype, the present study highlights the predominant role of the BRAF status in the cardiovascular involvement in ECD. Thus, the prevalence of the BRAF V600E mutation was a key independent determinant of both AI and CI, with 86% of carriers of the mutation exhibiting cardiovascular infiltration of histiocytes. Although hypoalphalipoproteinemia was restricted to male patients carrying the BRAF V600E mutation, these 2 parameters are independent determinants in AI. Moreover, an analysis of the blood CD14 + cell gene expression failed to detect any significant changes between BRAF V600E carriers and noncarriers, suggesting that in contrast to the proposed role of HDL, the BRAF status does not modulate CD14 + cells infiltration into the aorta. Taken together, our findings lead us to propose a model through which both the HDL phenotype and the BRAF status affect AI in ECD. Thus, the independent contribution of HDL-C in AI might involve the modulation of the inflammatory signature of blood CD14 + cells (CXCL1). Beyond of the static quantification of HDL-C, CEC, a metric of HDL function, might also contribute in an independent way to AI through modulation of the inflammatory signature of blood CD14 + cells (CX3CR1). Then, the BRAF V600E mutation might promote AI through effects that are both dependent (HDL-C and CEC) and independent of the HDL phenotype, these latter remaining to be identified ( Figure 5) . Thus, further studies are necessary to identify the role of the BRAF V600E mutation in the heart involvement in ECD. Interestingly, as previously reported in few ECD patients, 39, 40 an examination of computed tomographic scans in a few patients included in the present study before and after vemurafenib treatment clearly revealed a reduction of AI, although these patients still exhibited a coated aorta.
Our study provides new and important information in the understanding of the mechanisms contributing to lipid-laden histiocyte formation and heart involvement in ECD, which must be taken into account for the management of these patients. Although statins are very efficient at reducing plasma LDL-C levels, this class of drugs is mostly ineffective at robustly raising HDL-C levels. 41 Accordingly, plasma HDL-C and ApoA-I levels in ECD patients receiving statins or others lipid-lowering therapies exhibited hypoalphalipoproteinemia in a similar fashion compared with untreated patients in the present study. The development of HDL-based therapies is currently ongoing for the treatment of CVD, and a recent study reported that the infusion of small HDL, in the form of human ApoA-I reconstituted with phosphatidylcholine, led to the formation of highly functional HDL with an increased CEC through the ABCA1 pathway. 42 Such a therapy might provide benefits for ECD patients displaying a low HDL phenotype by reducing foamy histiocytes and AI. However, vemurafenib seems to be the , TC, HDL-C, CEC, Hypertension and Log CRP factors in the determination of aortic infiltration. BMI indicates body mass index; BRAF, B-Raf proto-oncogene, serine/threonine kinase; CEC, cholesterol efflux capacity; CRP, C-reactive protein; HDL-C, high-density lipoprotein cholesterol; Lp(a), lipoprotein(a); OR, odds ratio; TC, total cholesterol; and TG, triglycerides. *Significant predictor of aortic infiltration in the logistic regression analysis.
preferential first-line therapy in BRAF-mutated ECD patients because a restoration of defective sera CEC and a marked improvement of AI were observed in patients treated with the inhibitor of the mutated BRAF. The targeted therapy with vemurafenib was demonstrated to be efficacious in both multisystemic and refractory ECD, 39 and it was recently reported to have a prolonged efficacy in patients with BRAF V600 -mutant ECD, warranting consideration as a new standard of care for these patients. 43 Our study indicates that vemurafenib might be equally efficacious at attenuating lipid-laden formation and infiltration into the aorta and then might improve the severe prognosis of ECD patients with cardiovascular involvement.
Although further investigations are required to decipher the complex mechanisms leading to histiocyte formation and cardiovascular infiltration, this study uncovers the critical independent role of hypoalphalipoproteinemia and the BRAF V600E mutation in aortic involvement in ECD. 
